News

TB Alliance launches landmark Phase 3 clinical trial aimed at shortening duration of TB treatment

TB Alliance has announced that it will conduct a landmark Phase 3 clinical trial aimed at shortening the treatment of drug sensitive and MDR-TB. The trial known as STAND (Shortening Treatments by Advancing Novel Drugs) will test the PaMZ drug regimen composed of two drug candidates not yet approved for TB, PA-824 (Pa) and moxifloxacin (M), in addition to existing antibiotic pyrazinamide (Z). The STAND trial will span over 50 sites in 4 continents and is expected to shorten the treatment of MDR-TB from 2 years to 6 months. Additional benefits of the novel regimen include its low cost and relative ease compared to existing treatments and its compatibility with HIV drugs.

The Bill and Melinda Gates Foundation has pledged financial support to TB Alliance for the STAND trial as well as the United Kingdom Department for International Development (DFID), US Agency for International Development (USAID) and other organizations.

For the official TB Alliance press release click here

Additional Coverage and Links

TB Alliance Grants Fosun Pharma Rights to Develop, Market Promising TB Cure in China

New and better drugs for MDR-TB on the horizon

More News
30 Mar 2021
Médecins Sans Frontières (MSF) published a press release on World TB Day 2021 announcing their clinical trial, TB-Practecal , investigating novel treatment for MDR-TB has stopped enrolling earlier than originally planned due to promising results. The trial's independent data safety and monitoring...
3 Feb 2021
Last week, the World Health Organization (WHO) held a consultation to discuss the definition of extensively drug resistant (XDR) tuberculosis. The meeting was held to discuss novel treatment regimens and diagnostics for drug-resistant TB and determine its impact on the definition of XDR-TB. The...
10 Dec 2020
The Stop TB Partnership Working Group on New TB Vaccines (WGNV), Working Group on New TB Drugs (WGND), and New Diagnostics Working Group (NDWG) are developing an online course specifically designed for advocates and affected communities to provide a base of knowledge in TB research and to generate...